15 closest matches · ranked by relevance
Cowden's Disease · Hamartoma Syndrome, Multiple
Primary: Biochemical Changes in Benign and Malignant Tumor Tissues as Assessed by Immunohistochemistry.
Medullary Thyroid Carcinoma · Multiple Endocrine Neoplasia Type 2A · Multiple Endocrine Neoplasia Type 2B
Primary: Maximum Tolerated Dose (MTD) — 100 mg/m^2/day
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Mitral Valve Insufficiency · Heart Failure
Primary: Change in Baseline Regurgitant Volume Associated With the Carillon Device Relative to the Control Population at 12 Months — -7.07; 3.32 ml/beat
Neuroendocrine Tumor · Anaplastic Thyroid Cancer · Adenocarcinoma
Primary: Objective Response Rate (ORR) — 0; 2; 2; 2 Participants
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Neuroendocrine Carcinoma of the Lung and Thymus
Primary: Percentage of Participants Progression-free at 9 Months Based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 0; 0; 0; 2.4 percentage of participants
Dysautonomia, Familial · Baroreflex Failure Syndrome
Primary: Number of Participants Who Reported Adverse Events Related to Study Drug — 0; 0; 0 Participants
Carcinoid Tumors · Pancreatic NET
Primary: Overall Radiographic Response Rate (ORR) — 0 Participants
Parkinson's Disease · Hyperprolactinemia
Primary: Number of Participants With Fibrotic Valvular Heart Disease Per 10,000 Participant-Years of Follow-Up — 21; 21; NA; 52 Participants/10,000 Participant-Years
Hereditary Cancer Syndrome
Primary: Positive Findings for Hereditary Cancer Syndromes — 28; 8; 4; 787 Participants
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Carcinoid Syndrome
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 22; 100 Participants